Education

Doctoral Seminar and Invited Lectures

One important module of the graduate education program at the IKP is the training of the structured preparation, presentation and discussion of own results to a larger audience. All PhD/MD students are given the opportunity to regularly report on the current progress of their research projects, usually one or two times a year mainly during lecture periods of the universities. The talks are seen as advanced training.

Also external speakers are invited to the IKP to share their expertise with both PhD/MD students and Post Docs.

Lectures sorted by year

05.03.2025    

Lea Vogt,  Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP)
NNMT as a potential therapeutic target in ccRCC

12.03.2025    

Joshua Busch,  Robert Bosch Center for Tumor Diseases (RBCT)
Examining the Role of Hyperactive Enhancers and their Transcripts (eRNAs) in Acute Myeloid Leukemia

09.04.2025       

Theresa Carlucci, r. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP)
The role of farnesoid X rceptor in human kidney physiology and pathophysiology

 

17.01.2024    

Hannah Heinrich,  Dr . Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP)
Role of the Nucleoside diphosphate kinase (NDPK) in primary tumors and metastases of renal cell carcinoma (RCC)

14.02.2024    

Natalie Widmann,  Dr . Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP)
Elucidation of Extracellular Vesicles for Drug Research

13.03.2024       

Onur Mert Batmaz, Robert Bosch Center for Tumor Diseases (RBCT)
Contribution of PLCG2 to Colorectal Cancer Development and Progression

10.04.2024       

Julia Dressler, Dr . Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP)
Endogenous metabolites and drugs as substrates of the organic anion transporters OAT2 and OAT7

12.06.2024       

Teodora Lukic, Robert Bosch Center for Tumor Diseases (RBCT)
Unraveling ΔNp63 Driven Transcriptional Reprogramming in Squamous Carcinogenesis: Comparative Omics Analysis

10.07.2024       

Akshay Kanakan, Robert Bosch Center for Tumor Diseases (RBCT)
Context specific role of SNAI2 in modulating lineage defining transcription factor networks in PDAC

02.10.2024       

Meghana Manjunath, Robert Bosch Center for Tumor Diseases (RBCT)
Impact of LSD1 Knockdown on Circular RNA Profiles and Associated Phenotypic Changes in PDAC

09.10.2024       

Tipack Ayothyapattanam Shanmugam, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP)
Characterization of Immune Landscape of Human Artherosclerotic Lesions

13.11.2024       

Patricia Raude, Robert Bosch Center for Tumor Diseases (RBCT)
Identification of key immune Players in CMS1 colorectal cancer

20.11.2024       

Marianna Dittrich, Robert Bosch Center for Tumor Diseases (RBCT)
The role of SPT5 in Cell Identity of Pancreatic Ductal Adenocarcinoma

11.12.2024       

Raya Rosok, Robert Bosch Center for Tumor Diseases (RBCT)
Cooperativity between the transcription factors GATA6 and ΔNp63 in Pancreatic Ductal Adenocarcinoma

17.12.2024       

Carlo Marggraf, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP
The Combination of Stauprimide and Barasertib is a promising new therapy Approach for clear cell renal carcinoma (ccRCC)

 

06.07.2023    

Sophia Steinlein ,  Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology , Stuttgart
Lymphoma associated stromal cells as an innovative therapeutic target for diffuse large B cell lymphoma

13.07.2023       

Sabrina Kalmbach , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms

20.09.2023       

Joanna Aggrey Fynn , Robert Bosch Center for Tumor Diseases (RBCT) , Stuttgart
Regulation of Pancreatic Cancer Metastasis by Signal Conversion in the Epigenome

11.10.2023       

Tobias Beigl , Robert Bosch Center for Tumor Diseases (RBCT) , Stuttgart
Novel insights into the transmembrane domain interactome of Bcl 2 proteins elucidated by a bimolecular split luciferase assay and it’s impact on apoptosis signalling

15.11.2023       

Julia Thiel , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Patient-derived precision-cut tumor slices as a tool to study CD3-bispecific antibody therapy in solid tumors

06.12.2023       

Thomas Ekstrom , Robert Bosch Center for Tumor Diseases (RBCT) , Stuttgart
Lineage defining transcription factors regulate PDAC subtype identity through distinct mechanisms

 

13.01.2022       

Svenja Wallisch, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
FORGI: Fibroblast tumor ORGanoids Immune cell co-culture – a new model to understand tumor microenvironment interactions

26.01.2022      

Prof. Markus Ketteler, MD, Robert Bosch Hospital, Stuttgart
Physiology and pathophysiology of the kidneys

27.01.2022      

Jing Yang, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Research the function of hOCT1 in Drosophila melanogaster expressing hOCT1 by feeding cisplatin and cimetidine

17.02.2022      

Marcel Lackner , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Establishment of Stable Isotope resolved Metabolomics as Test System to assess Membrane associated Drug Targets in Cancer

07.04.2022      

Charlotte Kölz , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Functional characterization of the two liver transporters OAT2 and OAT7 through in vitro methods and two novel mouse models

27.04.2022   

Prof. Andreas Hartkopf, MD, Clinic for Gynecology and Obstetrics at the University Hospital Ulm
Physiology and pathophysiology of the breast 

28.04.2022      

Simeon Rüdesheim , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Physiologically Based Pharmacokinetic Modeling to Describe and Predict the Activity Score-Dependent Metabolism of CYP2D6 Substrates

04.05.2022   

Prof. Peter Ong, MD, and Astrid Hubert, MD, Robert Bosch Hospital, Stuttgart
Physiology and pathophysiology of the cardiovascular System

12.05.2022      

Benjamin Schäfer , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Potential of BCL2 Inhibition in Ovarian Cancer Therapy

19.05.2022      

Sandra Weller , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
ABT-199 synergizes with PI via transactivation of NOXA

25.05.2022   

Prof. Kilian Rapp, MD, Robert Bosch Hospital, Stuttgart
Grundbegriffe der Geriatrie einschließlich besonderer Aspekte der Pharmakotherapie bei gebrechlichen Menschen 

02.06.2022   

Prof. Claus Neurohr, MD, RBK Lung Center Stuttgart, Clinic Schillerhöhe GmbH
Physiology and pathophysiology of the lung

15.06.2022   

Robyn Laura Kosinsky, PhD, Robert Bosch Center of  Tumor Diseases, Stuttgart
Intestinal inflammation and tumorigenesis –Pathogenesis, molecular classification and experimental tools

23.06.2022      

Christina Schräpel , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Physiologically Based Pharmacokinetic (PBPK) Modeling of Enclomiphene and its Metabolites Predicting Drug Drug Gene Interaction (DDGI) Scenarios

29.06.2022   

Prof. Marc Dahlke, MD, Robert Bosch Hospital, Stuttgart
Metastatic Disease from a Surgeons Perspective 

07.07.2022      

Tobias Beigl , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Brought to light: The interaction pattern of Bcl-2 transmembrane domains in a bimolecular luciferase complementation assay

13.07.2022   

Nikolaus Lubomierski, MD, Robert Bosch Hospital, Stuttgart
Novel Classification and Treatment of Diabetes Mellitus

14.07.2022      

Sophia Steinlein , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Lymphoma associated stromal cells as an innovative therapeutic target for diffuse large B cell lymphoma

01.09.2022      

Sabrina Kalmbach , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Global profiling of localized and systemic forms of follicular lymphoma: the relevance of molecular features in different clinical stages

22.09.2022      

Julia Thiel , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
The interplay between the tumo rmicroenvironment and drug therapy in precision-cut tissue slices

06.10.2022      

Selina Maier , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Anti-hormone therapy affects BKCa channel dependent K+ homeostasis in murine and human breast cancer cells

19.10.2022      

Prof. Hiltrud Brauch , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
How to write a paper for scientific publishing

27.10.2022      

Lena Sophie Menig , Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart
Heterogeneity of monocarboxylate transporter 1 and 4 (MCT1/MCT4) in clear cell renal cell carcinoma (ccRCC) and metastasis

23.11.2022      

Dr. Maaike van der Lee , Department of Clinical Pharmacy and Toxicology Leiden University Medical Centre
Long read sequencing and AI in pharmacogenomics

30.11.2022      

Prof. Dr. Albert Braeuning , German Federal Institute for Risk Assessment
Food safety at the German Federal Institute for Risk Assessment

 

Due to the Corona Pandemic lectures were still limited. 

 

16.06.2021      

Prof. Jörg Albert, MD, Robert Bosch Hospital, Stuttgart
Physiology and pathophysiology of the gastrointestinal tract

30.06.2021   

Christian Schäfer, MD, Robert Bosch Hospital, Stuttgart
Physiology and pathophysiology of the liver 

08.12.2021   

Prof. Olaf Rieß, MD, University Hospital, Tuebingen
Diagnostics of Rare Diseases: Beyond The Exome 

 

Due to the Corona Pandemic there were no lectures.

06.02.2019      

Prof. Uwe Fuhr, MD, University Hospital of the University of Cologne(BfR)
Pharmacokinetics

01.03.2019   

Prof. Volker Lauschke, PhD, Karolinska Institute, Stockholm
Inter-individual Differences in Drug Response - From Computational Predictions to Experimental Models 

05.06.2019   

Prof. Thomas Wider, MD, University Medical Center Tübingen
Immune Senescence Surveillance of Tumours 

10.07.2019      

Prof. German Ott, MD, Robert Bosch Hospital, Stuttgart
Diagnostic Pathology: A Method Bridging Classical Morphology and Molecular Genetics

17.07.20191   

Prof. Michael Schwarz, MD, University Hospital Tübingen
Mechanisms of Tumor Promotion  

06.11.2019   

Christina Justenhoven, PhD, Bioscientia - Institute of Medical Diagnostic GmbH, Ingelheim
Analysis of DNA variations  

20.11.2019   

Prof. Marius Üffing, PhD, University Tübingen
Proteomics - From basic approaches to clinical applications  

 

24.01.2018      

Prof. Albert Bräuning, PhD, German Federal Institute for Risk Assessment (BfR)
Food Safety at the German Federal Institute for Risk Assessments

17.10.2018   

Prof. Uwe Fuhr, MD, University Hospital of the University of Cologne
Pharmacokinetics - Basic Principles  

05.12.2018   

Prof. Klaus Mörike, MD, University Hospital Tübingen
Clinical Studies – Design and Realization 

06.12.2018      

Pavel Bashtrykov, PhD, University Stuttgart
Epigenetic silencing of oncogenes: a novel approach for targeted cancer therapy

 

24.05.2017      

Prof. Joerg Albert, MD, Robert Bosch Hospital
Physiology and pathophysiology of the digestive system

31.05.2017   

Christian Schäfer, MD, Robert Bosch Hospital
Physiology and pathophysiology of the liver  

31.05.2017   

Prof. Jun J. Yang, Ph.D., St. Jude Children's Research Hospital
Pharmacogenomics of Thiopurines and Precision Medicine: From Genomics to Clinical Actions 

14.06.2017      

Prof. Godehard Friedel, MD, Robert Bosch Hospital - Schillerhoehe
Physiology and pathophysiology of the lungs

21.06.2017      

Prof. Andreas Hartkopf, MD, University Hospital Tuebingen)
Physiology and pathophysiology of the breast

28.06.2017   

Prof. Kilian Rapp, MD, Robert Bosch Hospital
Physiological Specialties in Elderly Patients  

05.07.2017   

Prof. Peter Ong, MD, Robert Bosch Hospital
Physiology and pathophysiology of the cardiovascular System  

13.07.2017      

Prof. Robert Feil, PhD, University of Tuebingen
Seeing is believing: Combining biochemistry and mouse genetics to visualize physiology, pathophysiology and pharmacology

12.07.2017      

Martin Kimmel, MD, Robert Bosch Hospital
Physiology and pathophysiology of the kidneys

19.07.2017   

Prof. Andreas Nüssler, MD, University of Tuebingenm
Cell culture approaches towards 3D micro-organ Engineering  

18.09.2017   

Prof. Sven Glaesker, MD, University Hospital Brussels
Molecular and morphological pathogenesis in von Hippel-Lindau (VHL) disease 

08.11.2017      

Prof. Klaus Moerike, MD, University Hospital Tuebingen
Arzneimitteltherapie kardialer Arrhythmien

15.11.2017      

Prof. Robert Lukowski, PhD, University Hospital Tuebingen
The NO-cGMP system: Implications for disease biology and therapy

22.11.2017   

Reinhold Kerb, MD, CRS Clinical Research GmbHm
Drug Therapy of Diabetes, Obesity, Metabolic Syndrome  

29.11.2017   

Prof. Peter Muenzel, University of Tuebingen
Gifte und Vergiftungen  

08.12.2017      

Prof. Carsten Gruellich, MD, NCT -National Center for Tumor Diseases Heidelberg Medical Oncology
Molekulare Heterogenität und therapiegetriebene Evolution des Nierenzellkarzinoms

11.12.2017      

Markus Morkel, MD, Charité - University Hospital Berlin
Organoids as a tool to assess oncogene characteristics and cancer signaling networks

13.12.2017   

Prof. Robert Juette, PhD, Institute of the History of Medicine, Robert Bosch Stiftung
Der Placebo Effekt: Past and Present